Novo Nordisk Inc v. DR Reddy's Laboratories Ltd Do Not File In This Case

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Dr. Reddy's Laboratories, Ltd. (India) and Dr. Reddy's Laboratories, Inc. (New Jersey)
  • Plaintiff's Counsel: Saul Ewing LLP; Fenwick & West LLP
• Case Identification: 2:23-cv-22112, D.N.J., 11/08/2023
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Dr. Reddy's Laboratories, Inc. is a New Jersey corporation with its principal place of business in the state. For Defendant Dr. Reddy's Laboratories, Ltd., venue is based on its alleged physical presence, business activities, derivation of revenue, and prior consent to jurisdiction in the district through litigation activities.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's liraglutide injection product (Victoza®) constitutes an act of infringement of two U.S. patents related to the drug's formulation and its injection device.
• Technical Context: The dispute involves pharmaceutical formulations for GLP-1 agonists, a class of drugs used to treat type 2 diabetes, and the mechanical design of the push-button mechanism for pen-style injection devices used to administer such drugs.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's notification to Plaintiff on September 25, 2023, that it had filed an ANDA containing a Paragraph IV certification, asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by its proposed generic product. The complaint also notes related litigation involving the same plaintiffs and some of the same patents against other generic drug manufacturers.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833 - "Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and For Use in Injection Devices"

The Invention Explained

• Problem Addressed: The patent's background section describes problems with using mannitol, a common isotonicity agent in injectable peptide formulations ( Compl., Ex. A, '833 Patent, col. 1:30-34). The inventors observed that mannitol crystallizes during production, leading to deposits on filling equipment, and can also cause clogging of the fine-gauge needles used in injection devices '833 Patent, col. 1:34-45
• The Patented Solution: The invention is a pharmaceutical formulation that replaces mannitol with propylene glycol as the isotonicity agent '833 Patent, abstract This substitution is claimed to reduce deposits on production equipment and in the final drug product, as well as decrease the incidence of needle clogging, thereby improving manufacturing efficiency and the reliability of the injection device for the end-user '833 Patent, col. 1:52-58
• Technical Importance: The solution addresses key manufacturing and usability challenges for injectable peptide drugs, potentially increasing production yield and enhancing patient safety and convenience.

Key Claims at a Glance

• The complaint asserts infringement of all claims 1-31 Compl. ¶26
• Independent Claim 1, a composition claim, recites the following elements:
  • A pharmaceutical formulation comprising at least one GLP-1 agonist,
  • a disodium phosphate dihydrate buffer and
  • propylene glycol,
  • wherein said propylene glycol is present in said formulation in a final concentration of from about 1 mg/ml to about 100 mg/ml and
  • wherein said formulation has a pH of from about 7.0 to about 10.0.
• The complaint notes that claims 16-31 are directed to methods of preparing such formulations or methods of reducing deposits and clogging Compl. ¶26

U.S. Patent No. 9,265,893 - "Injection Button"

The Invention Explained

• Problem Addressed: The patent addresses the operational friction in pen-style injection devices where a user pushes a button to administer a dose '893 Patent, col. 1:15-21 In many such devices, the push button and the internal driving mechanism must rotate relative to each other during injection, creating friction that increases the force a user must apply '893 Patent, col. 1:46-51
• The Patented Solution: The invention is a push button connection designed to minimize this rotational friction. The core of the solution is a "pivot bearing" formed between the push button and the driving part, which minimizes the contact surface area and the radius of the resulting friction force '893 Patent, col. 1:51-57 '893 Patent, abstract The design also incorporates radial bearings to manage forces applied off-center on the push button, ensuring proper transfer of force to the driving mechanism '893 Patent, col. 1:58-2:2
• Technical Importance: By reducing the required injection force, the invention makes the device easier and more comfortable to operate, which is particularly significant for patients with reduced dexterity or hand strength who may require daily injections.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-6 Compl. ¶32
• Independent Claim 1 recites the following elements:
  • A push button connection for an injection device comprising:
  • a push button mountable on a driving part being rotatable relatively to the push button and which push button further comprises a bore with a bottom surface and
  • which bore surrounds a protrusion on the driving part which protrusion has a top surface and
  • wherein a pivot bearing is formed between the bottom surface and the top surface,
  • wherein when a user presses on the push button the force is directed toward the driving part and
  • wherein the driving part rotates relative to the push button.
• The complaint's assertion of claims 1-6 indicates that dependent claims, which add further structural limitations, are also at issue Compl. ¶32

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Defendant's proposed generic version of liraglutide injection, 18 mg/3 ml (6 mg/ml), for which it submitted ANDA No. 214411 to the FDA Compl. ¶7 Compl. ¶21 The complaint refers to this as "Dr. Reddy's Product" Compl. ¶8

Functionality and Market Context

• Dr. Reddy's Product is a generic pharmaceutical intended to be a substitute for Novo Nordisk's Victoza®, a widely used treatment for type 2 diabetes Compl. ¶1
• The complaint alleges that Defendant's ANDA relies on the Victoza® New Drug Application and contains data to demonstrate the bioequivalence of Dr. Reddy's Product to Victoza® Compl. ¶22
• The complaint does not provide specific details about the formulation of Dr. Reddy's Product or the specific injection device it will be marketed with, beyond the general allegation that their sale will infringe the patents-in-suit Compl. ¶26 Compl. ¶32

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint. The complaint makes general allegations of infringement without providing a detailed, element-by-element infringement theory or an accompanying claim chart. The analysis below is based on the conclusory allegations in the complaint.

'833 Patent Infringement Allegations

'893 Patent Infringement Allegations

Identified Points of Contention

• Factual Questions: The primary point of contention for both patents will be factual. For the '833 Patent, the dispute will center on the precise chemical composition of Dr. Reddy's proposed product as detailed in its ANDA. For the '893 Patent, the dispute will depend on the specific mechanical structure of the injection device Defendant intends to use, which is not identified in the complaint.
• Scope Questions: For the '893 Patent, a key legal question may arise regarding the scope of the term "pivot bearing" and whether the structure in Defendant's chosen device, once identified, falls within the proper construction of that term.

V. Key Claim Terms for Construction

The complaint does not identify any specific claim terms as a basis for non-infringement arguments. However, the following term from the '893 Patent is central to its inventive concept.

• The Term: "pivot bearing" (from '893 Patent, Claim 1)
• Context and Importance: This term is the core structural element of the claimed invention, intended to minimize rotational friction between the push button and the driving part. The entire infringement analysis for the '893 Patent will likely depend on whether the connection in the accused device constitutes a "pivot bearing" as claimed. Practitioners may focus on this term because it links a structural arrangement to a functional outcome.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim language itself is broad, defining the "pivot bearing" functionally as being "formed between the bottom surface [of the bore] and the top surface [of the protrusion]" '893 Patent, claim 1 Plaintiff may argue this language covers any interface between these two surfaces that allows for pivoting action to reduce friction.
  • Evidence for a Narrower Interpretation: The specification describes a specific embodiment where "the most proximal bottom surface 17 of the bore 12 is formed with a raised pointer forming a pivot 18" '893 Patent, col. 3:62-64 Defendant may argue that this disclosure limits the term "pivot bearing" to a structure involving a specific point-contact, rather than a broader surface-to-surface contact.

VI. Other Allegations

• Indirect Infringement: The complaint does not contain counts for indirect infringement under 35 U.S.C. § 271(b) or (c). The infringement allegations are based on the submission of the ANDA under 35 U.S.C. § 271(e)(2)(A), which is a statutory act of direct infringement Compl. ¶25 Compl. ¶31
• Willful Infringement: The complaint alleges that "Dr. Reddy's was aware of the '833 patent when it submitted its ANDA" and makes an identical allegation regarding the '893 patent Compl. ¶29 Compl. ¶35 Based on this alleged knowledge, the complaint asserts that the case is "exceptional" and seeks an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶29 Compl. ¶35 Prayer for Relief, F

VII. Analyst's Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two central questions that emerge from the complaint's allegations:

1. A core issue will be one of compositional identity: Does the confidential formulation data within Dr. Reddy's ANDA disclose a product that contains every element of Claim 1 of the '833 Patent, specifically the combination of a GLP-1 agonist, propylene glycol, and a disodium phosphate dihydrate buffer, all within the claimed concentration and pH ranges?

2. A key two-part question will be one of device structure and definitional scope: First, what is the specific design of the injection device that Dr. Reddy's will use to market its generic drug? Second, does the push button mechanism in that device contain a "pivot bearing" as that term is properly construed, or does it utilize a different mechanical interface to manage rotational forces?